Sign In
Buy HRMY
$35.24
-0.620 (-1.73%)
At Close: Jul 31, 2026
Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
07:30am, Tuesday, 04'th Nov 2025
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced earnings of $239.5M for Q3 2025, representing 29% year-over-year revenue growth for WAKIX®. T
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: Should You Buy?
11:01am, Tuesday, 28'th Oct 2025
Harmony Biosciences (HRMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harmony Biosciences (HRMY) Moves 12.7% Higher: Will This Strength Last?
05:41am, Friday, 24'th Oct 2025
Harmony Biosciences (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the ne
Harmony Biosciences Holdings, Inc. $HRMY Shares Sold by Allspring Global Investments Holdings LLC
03:46am, Friday, 24'th Oct 2025
Allspring Global Investments Holdings LLC lessened its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) by 5.5% in the second quarter, according to the company in its most recen
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Recommendation of “Moderate Buy” by Brokerages
01:42am, Friday, 24'th Oct 2025
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten brokerages that are presently covering the company, MarketBea
Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance
08:05am, Thursday, 23'rd Oct 2025
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced preliminary results for Q3 2025, highlighted by the following: WAKIX® (pitolisant) franchise
3 Biotech Stocks I Am Accumulating
02:30pm, Wednesday, 15'th Oct 2025
The biotech sector has underperformed the market for many years now, but there are reasons to be optimistic about this area of the market. Many biotech/biopharma stocks also make good covered call tra
HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
11:01am, Thursday, 25'th Sep 2025
Harmony Biosciences' shares plunge after ZYN002 failed in Fragile X, but Wakix sales and new epilepsy assets keep its pipeline moving forward.
Freeport-McMoRan, Harmony Biosciences, Cohu, And Other Big Stocks Moving Lower On Wednesday
02:18pm, Wednesday, 24'th Sep 2025
U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Wednesday.
Harmony Biosciences' genetic disorder drug fails to meet main goal in late-stage trial
08:33am, Wednesday, 24'th Sep 2025
Harmony Biosciences said on Wednesday its experimental drug for a type of rare genetic disorder failed to meet the main goal in a late-stage trial, sending its shares down 8% before the bell.
Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome
08:00am, Wednesday, 24'th Sep 2025
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN00
Harmony Biosciences Holdings, Inc. (HRMY) Presents at Cantor Global Healthcare Conference 2025 Transcript
01:09am, Friday, 05'th Sep 2025
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Cantor Global Healthcare Conference 2025 September 4, 2025 2:10 PM EDT Company Participants Jeffrey Dayno - President, CEO & Director Sandip Kapadia -
Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress
08:05am, Tuesday, 26'th Aug 2025
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy
Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference
08:05am, Thursday, 21'st Aug 2025
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2025 Cantor Global
Harmony Biosciences: Reiterating Buy Ahead Of Data Catalyst For Cannabinoid Drug
04:15pm, Wednesday, 20'th Aug 2025
Harmony Biosciences remains a Buy due to strong Wakix growth, profitability, and undervalued metrics despite recent setbacks. Upcoming catalysts—especially ZYN002 Phase 3 data in Fragile X—could d
